Wells Fargo & Co Reaffirms “Hold” Rating for Teva Pharmaceutical Industries (TEVA)

Wells Fargo & Co reiterated their hold rating on shares of Teva Pharmaceutical Industries (NYSE:TEVA) in a research report report published on Friday morning.

TEVA has been the topic of a number of other reports. Mizuho raised their target price on Teva Pharmaceutical Industries from $28.00 to $29.00 and gave the company a buy rating in a research report on Monday, September 17th. Jefferies Financial Group restated a hold rating and set a $21.00 target price on shares of Teva Pharmaceutical Industries in a research report on Friday, August 3rd. Cantor Fitzgerald set a $25.00 target price on Teva Pharmaceutical Industries and gave the company a hold rating in a research report on Friday, September 14th. Goldman Sachs Group raised shares of Teva Pharmaceutical Industries from a buy rating to a conviction-buy rating and set a $30.00 price target on the stock in a research note on Monday, October 1st. Finally, Credit Suisse Group lowered shares of Teva Pharmaceutical Industries from an outperform rating to a neutral rating and decreased their price target for the company from $25.00 to $23.00 in a research note on Friday, September 7th. Five research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average target price of $21.58.

NYSE:TEVA opened at $22.85 on Friday. Teva Pharmaceutical Industries has a 52 week low of $11.41 and a 52 week high of $25.96. The company has a debt-to-equity ratio of 1.75, a quick ratio of 0.61 and a current ratio of 0.94. The stock has a market cap of $22.97 billion, a PE ratio of 5.81, a price-to-earnings-growth ratio of 1.85 and a beta of 0.77.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Thursday, November 1st. The company reported $0.64 EPS for the quarter, beating the Zacks’ consensus estimate of $0.53 by $0.11. Teva Pharmaceutical Industries had a positive return on equity of 21.83% and a negative net margin of 54.67%. The firm had revenue of $4.53 billion for the quarter, compared to analysts’ expectations of $4.54 billion. During the same period last year, the firm earned $1.00 EPS. The company’s quarterly revenue was down 19.4% on a year-over-year basis. As a group, analysts expect that Teva Pharmaceutical Industries will post 2.72 EPS for the current fiscal year.

In related news, EVP Iris Beck Codner sold 4,165 shares of the firm’s stock in a transaction dated Thursday, August 9th. The shares were sold at an average price of $22.70, for a total value of $94,545.50. Following the transaction, the executive vice president now directly owns 8,290 shares of the company’s stock, valued at approximately $188,183. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Richard Daniell sold 2,488 shares of the firm’s stock in a transaction that occurred on Tuesday, September 18th. The stock was sold at an average price of $23.69, for a total transaction of $58,940.72. Following the completion of the transaction, the vice president now directly owns 2,488 shares in the company, valued at $58,940.72. The disclosure for this sale can be found here. Insiders sold a total of 10,350 shares of company stock worth $239,430 over the last ninety days. 0.43% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. First Republic Investment Management Inc. lifted its stake in Teva Pharmaceutical Industries by 30.1% in the 2nd quarter. First Republic Investment Management Inc. now owns 20,110 shares of the company’s stock worth $489,000 after purchasing an additional 4,657 shares in the last quarter. Global Financial Private Capital LLC lifted its stake in Teva Pharmaceutical Industries by 92.2% in the 2nd quarter. Global Financial Private Capital LLC now owns 23,632 shares of the company’s stock worth $575,000 after purchasing an additional 11,335 shares in the last quarter. Sei Investments Co. lifted its stake in Teva Pharmaceutical Industries by 26.8% in the 2nd quarter. Sei Investments Co. now owns 162,241 shares of the company’s stock worth $3,946,000 after purchasing an additional 34,305 shares in the last quarter. Benjamin F. Edwards & Company Inc. lifted its stake in Teva Pharmaceutical Industries by 553.3% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 22,361 shares of the company’s stock worth $544,000 after purchasing an additional 18,938 shares in the last quarter. Finally, Toronto Dominion Bank purchased a new position in Teva Pharmaceutical Industries in the 2nd quarter worth approximately $669,000. 65.10% of the stock is currently owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Recommended Story: What are the most popular ETFs

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply